Oncology

High tumor fraction after induction chemotherapy identifies a population with an unmet need who has low chances to benefit from immune checkpoint blockades.

Findings presented at the American Society of Clinical Oncology (ASCO) 2023 meeting show the long-term efficacy and safety profile of larotrectinib (Vitrakvi; Bayer) in solid tumors with NTRK gene fusion.

Obe-cel is an investigational CD19 CAR T-cell therapy currently in clinical trials for relapsed/refractory B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma.

Ribociclib (Kisqali) demonstrated a 26% risk reduction in distant disease-free survival and a 28% risk reduction in recurrence-free survival in patients with HR+/HER2- early breast cancer.

The 2023 ASCO Annual Meeting is being held in Chicago, Illinois from June 2 to 6.

Investigators previously reported a statistically significant improvement in radiographic progression-free survival in the full intention-to-treat population of adults with deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer.

Psilocybin and other psychedelics hold promise in treating anxiety, depression, substance abuse and addiction, posttraumatic stress disorder, obsessive compulsive disorder, headaches, and chronic pain disorders.

Former and current smokers showed higher mortality from early-stage non-small cell lung cancer than never smokers.

Repotrectinib is a promising next-generation tyrosine kinase inhibitor under investigation for the treatment of ROS1-positive locally advanced or metastatic non-small cell lung cancer.

In the initial cohort, 63% of patients with advanced melanoma achieved an objective response rate, including 6 who had a complete response and 19 who had a partial response to the combination of fianlimab and cemiplimab.

Study shows 18.4% of patients with relapsed or refractory chronic lymphocytic leukemia treated with lisocabtagene maraleucel achieved a complete response (CR), with median duration of CR not reached at median follow-up of 21.1 months.

Multiple myeloma treatment selection is critical due to the potential for developing treatment resistance over time to the currently prescribed drugs.

With no treatments currently FDA approved, patients arrive at the hospital with no options for treatment beside waiting for the intoxication to pass.

Program Chair Ryan Haumschild, PharmD, MS, MBA, discussed what attendees can look forward to at the inaugural Oncology Pharmacists Connect meeting.

Decentralization has already been shown to streamline clinical trials, but it also has the potential to improve the broader health care ecosystem.

Overweight or obesity between middle and later adulthood had a statistically significant risk for noncolorectal gastrointestinal cancer.

Research has shown these programs can increase the number of patients who can access targeted treatments.

Weight loss that began as far as 2 years before a lung cancer diagnosis was associated with a risk of cancer.

The protozoan intranasal treatment was associated with a strong increase of immune cells within the lung.

Specialty pharmacists—those caring for patients with serious, sometimes life-threatening conditions such as cancer or rheumatologic disease—are not immune from the ongoing labor crisis.

The imaging agent and visualization system will be an adjunct to standard of care to reduce residual cancer in the lumpectomy cavity during initial surgery.

Understanding causes, consequences proves vital to develop therapies that exploit vulnerabilities of the cancer cells.

Treatment with epcoritamab-bysp showed a 61% overall response rate and a 38% complete response rate in heavily pretreated patients with R/R DLBCL.

The panel corresponds to proteins that are abundant in treatment-resistant melanoma cells and may predict resistance to targeted treatment.

Pegfilgrastim-pbbk is a leukocyte growth factor developed to reduce the onset of infection in patients with non-myeloid malignancies administered myelosuppressive anticancer medications associated with a clinically significant rate of febrile neutropenia.

Precision medicine is rooted in the reality that the way patients respond to treatment is heavily affected by their individual genetic variability, their complex biology, and external factors.

Fran Gregory, PharmD, MBA, vice president of Emerging Therapies at Cardinal Health, discussed the role biosimilars are playing in the pharmaceutical market as well as in patient access.